We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+39.29%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$646M
AUM Growth
+$3.57M
Cap. Flow
-$92.1M
Cap. Flow %
-14.26%
Top 10 Hldgs %
76.2%
Holding
43
New
2
Increased
4
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$9.36M
2
JSPR icon
Jasper Therapeutics
JSPR
+$9.33M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.86M
4
ADVM
Adverum Biotechnologies
ADVM
+$4.44M
5
VTVT icon
vTv Therapeutics
VTVT
+$2.11M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$115M
2
JANX icon
Janux Therapeutics
JANX
+$3.92M
3
PEPG icon
PepGen
PEPG
+$2.97M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$2.44M
5
ACLX
Arcellx
ACLX
+$431K

Sector Composition

Rank Sector Weight
1 Healthcare 99.72%
2 Financials 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
26
DELISTED
Adverum Biotechnologies
ADVM
$4.12M 0.64%
+291,666
New +$4.44M
PRME icon
27
Prime Medicine
PRME
$559M
$3.78M 0.59%
540,304
+70,000
+15% +$531K
DAWN
28
DELISTED
Day One Biopharmaceuticals
DAWN
$3.24M 0.5%
196,425
– –
CYPH
29
Cypherpunk Technologies Inc
CYPH
$73.3M
$1.78M 0.28%
669,303
– –
IGMS
30
DELISTED
IGM Biosciences
IGMS
$1.49M 0.23%
154,664
– –
BOLT icon
31
Bolt Biotherapeutics
BOLT
$7.78M
$1.47M 0.23%
52,458
– –
TERN
32
DELISTED
Terns Pharmaceuticals
TERN
$1.33M 0.21%
202,348
– –
ACRS icon
33
Aclaris Therapeutics
ACRS
$869M
$863K 0.13%
696,171
– –
VIRX
34
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$704K 0.11%
689,709
– –
ALLK
35
DELISTED
Allakos
ALLK
$217K 0.03%
172,089
– –
KRON
36
DELISTED
Kronos Bio
KRON
$102K 0.02%
78,131
– –
KLRS
37
Kalaris Therapeutics
KLRS
$96.8M
$62.2K 0.01%
3,580
– –
NUVB.WS
38
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$40.3K 0.01%
133,333
– –
SRZNW icon
39
Surrozen Inc Warrant
SRZNW
$8.86K
$3.02K ﹤0.01%
99,999
– –
PEPG icon
40
PepGen
PEPG
$197M
– –
-436,813
Closed -$2.97M
SNCE
41
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-45,000
Closed -$240K
RYZB
42
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-1,845,948
Closed -$115M
RAIN
43
DELISTED
Rain Oncology Inc. Common Stock
RAIN
– –
-2,034,552
Closed -$2.44M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q1 2024 Portfolio in Review

As of Q1 2024, Samsara BioCapital held 43 positions worth $646M, up 0.56% from $643M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Samsara BioCapital withdrew a net $92.1M in Q1 2024, closing 4 positions and reducing 2 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $115M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in Jasper Therapeutics worth $15.4M.

  • Samsara BioCapital's largest Q1 2024 buy was Jasper Therapeutics: 525,000 shares worth $15.4M.
  • Samsara BioCapital added most to Nkarta in Q1 2024, an estimated $9.36M increase.
  • Samsara BioCapital's biggest Q1 2024 reduction was Janux Therapeutics, cutting an estimated $3.92M.
  • Samsara BioCapital fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $115M.
  • Samsara BioCapital's ten largest holdings make up 76% of its $646M portfolio in Q1 2024.
  • Samsara BioCapital opened 2 new positions and closed 4 in Q1 2024.
  • Samsara BioCapital's portfolio value rose 0.56% quarter-over-quarter to $646M.

Based on Samsara BioCapital's 13F filing for Q1 2024, filed 15 May 2024.